Morepen LaboratoriesNSE:MOREPENLAB +2.82%74 PS Ratio is 1.66 as of Jun. 29, 2026, which is 19% above its 10-year median of 1.40. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹50.02 (Fairly Valued). The stock has 6 warning signs investors should review. Among 949 Drug Manufacturers companies, Morepen Laboratories ranks better than 60.91% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Morepen Laboratories's share price is ₹54.66.
Morepen Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹32.89. Hence, Morepen Laboratories's PS Ratio for today is 1.66.
The historical rank and industry rank for Morepen Laboratories's PS Ratio or its related term are showing as below:
NSE:MOREPENLAB'
s PS Ratio Range Over the Past 10 Years
Min: 0.48 Med: 1.4 Max: 6.38
Current: 1.67
During the past 13 years, Morepen Laboratories's highest PS Ratio was 6.38. The lowest was 0.48. And the median was 1.40.
NSE:MOREPENLAB's PS Ratio is ranked better than 60.91% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs NSE:MOREPENLAB: 1.67
Morepen Laboratories Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Morepen Laboratories was -2.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.20% per year.
During the past 13 years, Morepen Laboratories's highest 3-Year average Revenue per Share Growth Rate was 25.20% per year. The lowest was -14.30% per year. And the median was 12.70% per year.
Back to Basics: PS Ratio
Morepen Laboratories (NSE:MOREPENLAB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Morepen Laboratories PS Ratio Related Terms
Morepen Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Morepen Laboratories's Share Price of today is ₹54.66. Morepen Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹32.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Morepen Laboratories (NSE:MOREPENLAB) has a PS Ratio of 1.66 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Morepen Laboratories and its competitors. This is 19% above median its historical median of 1.40. Over the past decade, Morepen Laboratories' PS Ratio has ranged from 0.48 to 6.38. According to the industry distribution chart, Morepen Laboratories ranks #371 out of 949 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Morepen Laboratories' PS Ratio too high?
Morepen Laboratories' current PS Ratio of 1.66 is 19% above median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 6.38. The Drug Manufacturers industry median PS Ratio is 2.25. Morepen Laboratories' value of 1.66 is 26.2% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #371 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #371 out of 949 companies for PS Ratio. This puts Morepen Laboratories in the upper half of its industry. The industry median PS Ratio is 2.25. Morepen Laboratories' value of 1.66 is 26.2% below this benchmark. Historically, Morepen Laboratories' own PS Ratio has ranged from 0.48 to 6.38 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 2.25, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.25, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current PS Ratio of 1.66 is 26.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current PS Ratio is 1.66, which is 19% above median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹50.02, compared to a current price of ₹54.66 — trading 9.3% above its estimated fair value. The current PS Ratio is 1.66, which is 19% above median its 10-year median of 1.40 and 26.2% below the Drug Manufacturers industry median of 2.25. Morepen Laboratories' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current PS Ratio is 1.66 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹54.66 is trading 9.3% above its estimated GF Value™ of ₹50.02.
GuruFocus considers Morepen Laboratories to be Fairly Valued.
Key valuation signals for NSE:MOREPENLAB:
PS Ratio: 1.66 (19% above median its 10-year median of 1.40)
GF Value™: ₹50.02 vs. price of ₹54.66 (9.3% above fair value)
Industry Position: 26.2% below the Drug Manufacturers median (#371 of 949)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score
Get the complete analysis for NSE:MOREPENLAB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
